Xena Alakailly1, Raja Kummoona2, Faisal A Quereshy3, Dale A Baur3, Ariadne E González3. 1. Maxillofacial Surgery, Iraqi Board for Medical Specializations, Medical City, Baghdad, Iraq ; Department of Oral and Maxillofacial Surgery, School of Dental Medicine, University Hospitals/Case Medical Center, 2124 Cornell rd., Cleveland, OH USA ; Department of Oral and Maxillofacial Surgery, School of Dental Medicine, Case Western Reserve University, 2124 Cornell rd., Cleveland, OH 44106-4905 USA. 2. Maxillofacial Surgery, Iraqi Board for Medical Specializations, Medical City, Baghdad, Iraq. 3. Department of Oral and Maxillofacial Surgery, School of Dental Medicine, University Hospitals/Case Medical Center, 2124 Cornell rd., Cleveland, OH USA.
Abstract
INTRODUCTION: Vascular malformations have devastating cosmetic effects in addition to being associated with pain and bleeding. Sclerotherapy has been used as an effective therapeutic modality for the management of vascular malformations. The purpose of this case series is to describe our clinical experience of using sodium tetradecyl sulphate (STS) 3 % in the treatment of venous malformation lesions of head and neck. MATERIALS AND METHODS: Thirteen patients were included in this study (three male and ten female; age range between 8 months and 54 years; mean age 18.2 years, ±SD 15.71). The patients were treated by 3 % STS intralesional injections. Of the thirteen patients treated, complete resolution occurred in four patients (28.57 %), a good response occurred in five patients (35.7 %), a moderate response in two patients (14.28 %), a mild response in two patients (14.28 %) and no response in one patient (7.14 %). The side effects encountered in all patients were pain and edema after injection which was controlled by oral analgesics and an intramuscular injection of dexamethasone. In addition, two patients developed a superficial ulceration (11.76 %) which healed uneventfully, and one patient developed ecchymosis after injection (5.88 %). CONCLUSION: Sclerotherapy with 3 % STS is a simple, safe, and effective modality for the treatment of venous malformations.
INTRODUCTION:Vascular malformations have devastating cosmetic effects in addition to being associated with pain and bleeding. Sclerotherapy has been used as an effective therapeutic modality for the management of vascular malformations. The purpose of this case series is to describe our clinical experience of using sodium tetradecyl sulphate (STS) 3 % in the treatment of venous malformation lesions of head and neck. MATERIALS AND METHODS: Thirteen patients were included in this study (three male and ten female; age range between 8 months and 54 years; mean age 18.2 years, ±SD 15.71). The patients were treated by 3 % STS intralesional injections. Of the thirteen patients treated, complete resolution occurred in four patients (28.57 %), a good response occurred in five patients (35.7 %), a moderate response in two patients (14.28 %), a mild response in two patients (14.28 %) and no response in one patient (7.14 %). The side effects encountered in all patients were pain and edema after injection which was controlled by oral analgesics and an intramuscular injection of dexamethasone. In addition, two patients developed a superficial ulceration (11.76 %) which healed uneventfully, and one patient developed ecchymosis after injection (5.88 %). CONCLUSION: Sclerotherapy with 3 % STS is a simple, safe, and effective modality for the treatment of venous malformations.
Entities:
Keywords:
Head and neck; STS; Sclerotherapy; Sotradecol; Vascular malformations (VM); Venous malformation (VnM)
Authors: F Cornelis; A Neuville; C Labrèze; M Kind; B Bui; D Midy; J Palussière; N Grenier Journal: Cardiovasc Intervent Radiol Date: 2012-06-22 Impact factor: 2.740
Authors: Kong T Tan; John Kirby; Dheeraj K Rajan; Eran Hayeems; John R Beecroft; Martin E Simons Journal: J Vasc Interv Radiol Date: 2007-03 Impact factor: 3.464
Authors: Johnathon Gorman; Steven J Zbarsky; Rebecca J M Courtemanche; Jugpal S Arneja; Manraj K S Heran; Douglas J Courtemanche Journal: CVIR Endovasc Date: 2018-06-28